Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryna Kriachok, Meletios A. Dimopoulos, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Ganna Usenko, Roman Hajek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don Ambrose Stevens, Hang QuachSundar Jagannath, Phillipe Moreau, Moshe Levy, Ashraf Badros, Larry D. Anderson, Nizar J. Bahlis, Thierry Facon, Maria Victoria Mateos, Michele Cavo, Hua Chang, Yosef Landesman, Yi Chai, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Sebastian Grosicki, Paul G. Richardson

IM-Hem Onc BMT
Internal Medicine

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Sort by
Weight
Alphabetically

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Fingerprint

Medicine & Life Sciences